{"id":"NCT01849289","sponsor":"Novo Nordisk A/S","briefTitle":"A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes","officialTitle":"A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes (BEGIN™: ONCE)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-06-02","primaryCompletion":"2014-05-15","completion":"2014-05-15","firstPosted":"2013-05-08","resultsPosted":"2016-01-14","lastUpdate":"2017-04-07"},"enrollment":833,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"Insulin Degludec","otherNames":["NN1250"]},{"type":"DRUG","name":"Insulin Glargine","otherNames":[]}],"arms":[{"label":"Insulin Degludec","type":"EXPERIMENTAL"},{"label":"Insulin Glargine","type":"EXPERIMENTAL"}],"summary":"This trial was conducted in Africa, Asia, Europe, North and South America. The aim of the trial was to compare efficacy and safety of insulin degludec and insulin glargine in insulin naïve subjects with type 2 diabetes.","primaryOutcome":{"measure":"Change From Baseline in HbA1c (%) (Analysed by Central Laboratory)","timeFrame":"Week 0, week 26","effectByArm":[{"arm":"IDeg OD","deltaMin":-1.3,"sd":1.1},{"arm":"IGlar OD","deltaMin":-1.2,"sd":1}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":81,"countries":["United States","Brazil","Canada","China","Romania","South Africa","Ukraine"]},"refs":{"pmids":["27098525","28870034"],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":553},"commonTop":["Upper respiratory tract infection","Nasopharyngitis"]}}